Benzinga | Nov 9, 2021 11:35AM EST

Raymond James Maintains Strong Buy on Apellis Pharmaceuticals, Raises Price Target to $116

Raymond James analyst Steven Seedhouse maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Strong Buy and raises the price target from $102 to $116.